The Relationship Between Vitamin D and Parathyroid Hormone: Calcium Homeostasis, Bone Turnover, and Bone Mineral Density in Postmenopausal Women with Established Osteoporosis
Overview
Authors
Affiliations
It is evident from several studies that not all patients with hypovitaminosis D develop secondary hyperparathyroidism. What this means for bone biochemistry and bone mineral density (BMD) remains unclear. The aim of this study was to investigate the effects of hypovitaminosis D (defined as a 25OHD < or = 30 nmol/l) and patients with a blunted PTH response (defined arbitrarily as a PTH within the standard laboratory reference range in the presence of a 25OHD < or = 30 nmol/l) in comparison to patients with hypovitaminosis D and secondary hyperparathyroidism (defined arbitrarily as a PTH above the standard laboratory reference range in the presence of a 25OHD < or = 30 nmol/l) and vitamin D-replete subjects (25OHD > 30 nmol/l). Four hundred twenty-one postmenopausal women (mean age: 71.2 years) with established vertebral osteoporosis were evaluated by assessing mean serum calcium, 25OHD, 1,25(OH)2D, bone turnover markers, and BMD. The prevalence of hypovitaminosis D was 39%. Secondary hyperparathyroidism was found in only one-third of these patients who maintained calcium homeostasis at the expense of increased bone turnover relative to the vitamin D-replete subjects (bone ALP mean difference: 43.9 IU/l [95% CI: 24.8, 59.1], osteocalcin: 1.3 ng/ml [95% CI: 1.1, 2.5], free deoxypyridinoline mean difference: 2.6 nmol/nmol creatinine [95% CI: 2.5, 4.8]) and bone loss (total hip BMD mean difference: 0.11 g/cm2 [95% CI: 0.09, 0.12]). Patients with hypovitaminosis D and a blunted PTH response were characterized by a lower serum calcium (mean difference: 0.07 mmol/l [95% CI: 0.08, 0.2]), a reduction in bone turnover (bone ALP mean difference: 42.4 IU/l [95% CI: 27.8, 61.9], osteocalcin: 1.6 ng/ml [95% CI: 0.3, 3.1], free-deoxypyridinoline mean difference: 3.0 nmol/nmol creatinine [95% CI: 1.9, 5.9]), but protection in bone density (total hip BMD mean difference: 0.10 g/cm2, [95% CI: 0.08, 0.11]) as compared to those with hypovitaminosis D and secondary hyperparathyroidism. This study identifies a distinct group of patients with hypovitaminosis D and a blunted PTH response who show a disruption in calcium homeostasis but protected against PTH-mediated bone loss. This has clinical implications with respect to disease definition and may be important in deciding the optimal replacement therapy in patients with hypovitaminosis D but a blunted PTH response.
Evaluation of the age-specific relationship between PTH and vitamin D metabolites.
Povaliaeva A, Zhukov A, Bogdanov V, Bondarenko A, Senko O, Kuznetsova A Bone Rep. 2024; 22:101800.
PMID: 39281298 PMC: 11399804. DOI: 10.1016/j.bonr.2024.101800.
Liu Y, Gong C, Li J, Ning X, Zeng P, Wang L Front Nutr. 2024; 11:1439279.
PMID: 39279896 PMC: 11392846. DOI: 10.3389/fnut.2024.1439279.
Evaluation of Bone Markers in Type 2 Diabetes Mellitus.
Singh H, Kumar V, Singh A, Chaudhary S Ann Afr Med. 2024; 23(3):324-327.
PMID: 39034554 PMC: 11364324. DOI: 10.4103/aam.aam_71_23.
Vitamin D, PTH, and Lipid Dysregulation in Osteoarthritis: A Case-Control Study.
Mani A, Joseph P, Choudary D, Jeyaraman N, Ramasubramanian S, Karthik K J Orthop Case Rep. 2024; 14(6):177-185.
PMID: 38910978 PMC: 11189062. DOI: 10.13107/jocr.2024.v14.i06.4544.
Okumura G, Yamamoto N, Suzuki H, Ninomiya H, Hirano Y, Tei Y J Bone Miner Metab. 2024; 42(2):214-222.
PMID: 38329506 DOI: 10.1007/s00774-024-01495-6.